Login to Your Account

China’s Largest Biotech Expands Global Footprint

Shanghai Fosun Inks $531M Deal with Swiss Giant Sellas

By Cornelia Zou
Contributing Writer

Wednesday, October 23, 2013

HONG KONG – Looking to expand its global footprint, China’s largest biotech, Shanghai Fosun Pharmaceutical Group, has inked a potential $531 million deal with Switzerland’s Sellas Clinicals Holding Ag for two drug candidates. The deal not only gives Fosun cash to continue its focus on drug development, but also allows Sellas to diversify its product offerings and sources of new drugs.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription